1. 1) Coleman RE. Skeletal complications of malignancy. Cancer, 80 (Suppl.), 1588–1594 (1997).
2. 2) Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res., 12, 6243s–6249s (2006).
3. 3) Saad F, Gleason D, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes J, Goas J, Chen B, Group ZAPCS, Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl. Cancer Inst., 94, 1458–1468 (2002).
4. 4) Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J. Zoledronic Acid versus Placebo in the Treatment of Skeletal Metastases in Patients with Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J. Clin. Oncol., 21, 3150–3157 (2003).
5. 5) Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J. Clin. Oncol., 23, 3314–3321 (2005).